Find an expert

I obtained a Diploma in Chemistry from the University of Bern in Switzerland in 1992. Upon receiving the award of an International Postgraduate Research Scholarship (IPRS) I joined The University of Queensland (UQ) in 1993 to carry out research towards a PhD in Biochemistry(supervisors: Assoc. Profs. Peter Nixon and Ron Duggleby). I graduated in 1997 and continued postdoctoral research at UQ under the guidance of Profs John de Jersey, Susan Hamilton and Graeme Hanson. During this period, I was awarded Fellowships from both the Wellcome Trust and UQ. In 2000 I spent several months in the Department of Chemistry at the University of Newcastle-upon-Tyne, England, collaborating with Prof. Geoff Sykes, and later that year I commenced a Senior Postdoctoral Fellowship in the Chemistry Department at Stanford University (advisor: Prof. Edward Solomon). In 2003 I was appointed to a Lectureship in (Bio)Physical Chemistry at UQ. In 2006 I was promoted to Senior Lecturer. Following the award of a UQ Foundation Research Excellence Award (in 2007) I was promoted to Associate Professor (in 2008), and between 2011 and 2013 I was also on a fractional professorial appointment (50%) at Maynooth University, Ireland. From 2013 to 2017 I held a Future Fellowship from the Australian Research Council, and during this period I was promoted to Full Professor at UQ (2015). I also hold affiliate professorships in the Sustainable Minerals Institute and the Australian Institute for Bioengineering and Nanotechnology, both located at UQ.

I have successfully focused my research on the investigation of enzyme-catalysed reactions, their optimisation for applications in biotechnology and the synthesis of small molecules that mimic their structure and catalytic function (i.e. biomimetics). I advanced understanding of the contribution of metals to enzyme-catalysed reactions and employed state-of-the-art technologies (e.g. cryo-EM, ancestral gene reconstruction) to develop enzyme inhibitors as leads for novel biocides (herbicides, fungicides, antibacterial compounds) and engineer enzymes with enhanced catalytic properties for industrial applications in the advanced manufacturing sector (i.e. cell-free enzyme cascades, next-gen fertilisers). My work into enzyme mechanisms, regulation and engineering received international acclaim evidenced by invitations to provide plenary and keynote lectures and review articles in prestigious journals. I have published over 250 peer-reviewed articles, including over 40 papers in the ACS staple (J. Am. Chem. Soc, ACS Catalysis, ACS Sus. Chem. Eng., Inorg. Chem, Chem. Rev., Acc. Chem. Rev.) as well as landmark studies in Nature, Nature Catalysis, Nature Communications and Proc. Natl. Acad. Sci. (USA). For my leadership in enzymology I was awarded a Future Fellowship by the Australian Research Council, a Foundation Research Excellence Award by UQ and, most recently, the prestigious role as Ambassador for the Technical University of Munich (TUM), an honour bestowed upon me also for my leading role in building an extensive network of collaborations between UQ and TUM in the areas of bioengineering and bioeconomy. The network has since evolved into the Global Bioeconomy Alliance.

My research interests are in the field of Chemistry education, particularly how students learn in the chemistry laboratory.

I teach biological inorganic chemistry at a second and Masters level, as well as a broad range of topics in first year chemistry. I also teach the ethics of chemistry in second year.

Mariusz Skwarczynski completed his Ph.D. in Chemistry in 1999 at Wroclaw University of Technology (Poland). His postdoctoral training began at Tokushima Bunri University (Japan) under the direction of late Professor M. Nishizawa, where he studied the biomimetic total synthesis of anticancer agent paclitaxel. He then joined the laboratory of Professor Yoshiaki Kiso at Kyoto Pharmaceutical University (Japan) to study prodrugs of paclitaxel. In 2004 he was awarded with Japanese fellowship (Japan Society for the Promotion of Science postdoctoral fellowship) and research grant to conduct further research on paclitaxel. He developed novel classes of paclitaxel prodrugs: isotaxoids and phototaxels. He also co-developed an epimerization-free method for the synthesis of novel building blocks (isodipeptides) for solid phase peptide synthesis and these units have been commercialized by Merck-Novabiochem.

In 2008 he joined Professor Istvan Toth group at University of Queensland (Australia) to work on vaccine delivery strategies. Since then, he research is mainly focused on nanotechnology-based peptide vaccine delivery approaches. In 2010 he was awarded with University of Queensland Strategic Fund Research Fellowship. In Australia, he is involved in a wide range of collaborative research projects, both nationally and internationally, to develop vaccines against GAS, HIV, hookworm infections, malaria and cancer, along with antibiotics against multidrug resistant bacteria.

Dr. Alex Smith is a Research Fellow in Glycotherapeutics at UQ's School of Chemical Engineering. His interests are in understanding structure: function relationships between complex carbohydrates (such as heparan sulphate) and proteins, and how these interactions can inform the development of glycotherapeutic agents to treat a wide variety of injuries and diseases.

I began my scientific career with a Bachelor of Science in Biochemistry and Chemistry, followed by a Bachelor of Science with First Class Honours in Chemistry from Massey University, New Zealand. My honours project focused on developing hydrogels for controlled peptide release in the gut. I then pursued a PhD at Massey University, working on synthetic anti-cancer drugs based on cyclodextrins.

After completing my PhD, I worked as a Research Officer at the New Zealand Veterinary Pathology Epicentre, refining my diagnostic research skills. I continued my career as a Postdoctoral Fellow at Kansas State University, contributing to the detection and surveillance of zoonotic diseases in the swine industry.

Currently, at the University of Queensland, I integrate my expertise in synthetic peptides with vaccine development. My research bridges medical and agricultural biotechnology, focusing on innovative adjuvants and vaccines that span medicinal chemistry, nanotechnology, and immunology, aiming to enhance both health outcomes and agricultural practices.

I am a medicinal and organic chemist

Studied organic chemistry at the University of Sydney, moved to UQ in 1993, then worked for Bayer in Germany, before moving back to Australia in 1996. Worked in Melbourne at the Victorian College of Pharmacy (now MIPS). I then returned to UQ in 2000 to the Fairlie lab where we design and synthesise new chemical entities to tackle human disease. Since 2012 I have been on extended medical leave and am currently an Adjunct Research Fellow, researching proteins from flaviviruses such as Dengue, West Nile, and Zika viruses, and the coronaviruses SARS, MERS, and SARS-CoV-2.

Critical Care Medicine focuses on supporting patients, often with one or multiple organ failures. Based at the largest Australian cardiac hospital, our research investigates better ways to support patients with heart and/or lung failure. We explore technological, pharmacological and engineering advances that could help our patients to live longer and better. Our group is world-renowned for clinically relevant large animal models, including heart failure, respiratory failure (ARDS), heart transplantation, sepsis, cardiogenic shock, and more. All our studies use hospital-grade equipment and follow the same clinical guideline to maximise translation. We actively take on honours, MPhil and PhD students from multi-disciplinary backgrounds (science, engineering, medicine, allied health), with a successful track record in supporting our students to secure their own grants and funding. Students are expected to contribute to other studies of the group. For more information about the group, please visit ccrg.org.au, and email if you are interested to join us.

Professor István Tóth is Chair in Biological Chemistry at The University of Queensland (UQ), Brisbane, Australia, and Affiliated Professorial Research Fellow at the Institute of Molecular Biosciences, UQ. He graduated with a degree in Chemical Engineering from the Technical University, Budapest, Hungary and was awarded his PhD for his Alkaloid Chemistry research. Professor Tóth undertook a postdoctoral fellowship at Carleton University, Ottawa Canada before returning to Hungary to work as a Research Associate, then Scientific Group Leader at the Central Research Institute for Chemistry, Hungarian Academy of Science. He joined the School of Pharmacy at the University of London in 1987 as a Senior Lecturer and Royal Society sponsored Senior Research Fellow. He became a Reader in Medicinal Organic Chemistry in 1994 and was awarded a Doctor of Science degree (DSc 1994) for his work in Drug Delivery (Hungarian Academy of Sciences), before relocating to the University of Queensland in 1998 where he has built a productive research group. Professor Tóth was a visiting professor at the School of Pharmacy, University of London (1994-2004) and at the Department of Bioengineering and Therapeutic Science, University of California, San Francisco (2011-2013). Professor Tóth’s major research interests are: drug delivery, immunoadjuvants, carbohydrates, lipids, peptides, nucleosides, and nucleotides. This research has attracted over $85 million in competitive grants, research contracts and investment funds in the past 10 years. Professor Tóth has over 500 peer-reviewed publications, 45 patents, and an excellent track record in research commercialisation. He is a one of key founders of Alchemia, Implicit Bioscience Pty Ltd, Neurotide Pty Ltd and TetraQ (the commercial arm of Centre of Integrated Preclinical Drug Development). Professor Tóth is an elected RACI Fellow and Fellow of the Queensland Academy of Arts and Sciences. and Feklloiw of the Hungarian Academy of Sciences (since 2016) In 2009 he was awarded the Adrian Albert award for sustained and outstanding research in medicinal biochemistry, and a Business/Higher Education Round Table (BHERT) Award for Outstanding Achievement in International Collaborative Research and Development he obtained the Doctor Honoris Causa degree at Semmelweis university budapest Hungary (2019). Professor Tóth was appointed as a member of the ARC College of Experts (2008-2010). He was the founding (2007) then the elected (2008-2009) President of the Australian Chapter of Controlled Release Society.

Karnaker's research interests are natural products, peptide-based drug discovery and development, formulation chemistry and non-viral gene delivery system. Karnaker co-inventor and developed a novel, bioresponsive disulphide-linker technology, which has been used for non-viral vectors, peptide-therapeutics for pain and cancer treatment. Karnaker is also keen interest for topical, mucosal drug delivery using a range of dendrimer, nano and microbubbles, lipid and polymer-based nanoparticle systems in conjugation with both biological and physical stimuli-responsiveness.

Karnaker received a PhD in Pharmaceutical Chemistry from The University Queensland under the supervision of Dr Harendra Parekh and Dr Defang Ouyang. Prior to PhD, he completed a Master degree in Pharmaceutical Analysis and Quality assurance (India). Also worked as analytical research and development chemist for one year in a Pharma company. Since 2016, he his working with Dr Parekh team on a range of Industry-funded research projects and his role involves from ideation, research plan, execution, product delivery to industry partners on major platforms such as peptide-based therapeutics, gene therapy and sol-gel technology.

My research interests are centred around the structure and function of venom and silk polypeptides produced by arthropods, and their use in biotechnology and medicine. I am a Postdoctoral Fellow in the King laboratory in the Institute for Molecular Bioscience, the University of Queensland, Australia. Currently, I am investigating the composition, function and evolution of neglected insect venoms produced by assassin bugs (Hemiptera: Reduviidae), robber flies (Diptera: Asilidae) and nettle caterpillars (Lepidoptera: Limacodidae).

Educated at the University of Copenhagen, Denmark, and the Australian National University, Canberra. Career at the Université de Lausanne, Switzerland, and the Universität Marburg, Germany. Professor and Chair of Organic Chemistry and Head of the Organic Chemistry Section, The University of Queensland from 1985. Emeritus professor from 2008. Chair of the National Committee for Chemistry of the Australian Academy of Science 2009-2014. Editor-in-Chief, Australian Journal of Chemistry 2008-15. Editor, Journal of Analytical and Applied Pyrolysis (Elsevier, IF 3.65) 2016-. Visiting Professor Université de Pau, France, 2011-19; Visiting Professor University of Kuwait 2014-18; Visiting Professor / Special Appointed Professor Hiroshima University 2014-18. Fellow of the Australian Academy of Science. Centenary Medal of the Australian Commonwealth 2003 for research in organic and physical chemistry. David Craig Medal of the Academy of Science 2014 for research in chemistry. JSPS Fellowship (Japan) 2014. Honorary doctorate, University of Pau, France, 2014. A.J. Birch Medal of the Royal Australian Chemical Institute (RACI) for ecellence in research in organic chemistry, 2014. Leighton Medal of the RACI 2018.

Research on Unusual Molecules and Reactive Intermediates: Synthesis and Reaction Mechanism. Heterocyclic chemistry. Pyrolysis reactions. Photochemistry

Research in the Wentrup group is concerned with the discovery of novel types of molecules with new and unusual bonding patterns. Such molecules are mostly highly reactive, and special methods are required both for their generation and for their detection. The group has developed these methods over many years and acquired world-class equipment for these purposes, including flash vacuum thermolysis apparatus, cryostats for matrix isolation of reaction products at cryogenic temperatures (down to 7 K), matrix and solution photochemistry equipment, infrared, UV and mass spectrometers, as well as modern computational facilities.

This research has resulted in the synthesis and characterization of many novel compounds, including extended cumulenes of the types RN=C=C=C=X, which themselves are used in the synthesis of many novel types of molecules, some of them of potential pharmaceutical interest (quinolone antibiotics; diazepines).

The research group has a world reputation in the field of carbene and nitrene chemistry, involving reactive intermediates with sextet carbon or nitrogen. These species are also very useful in synthesis, for example in the preparation of diazepines and diazepinones, a family of pharmaceutically interesting compounds. Numerous mechanistic studies and synthetic applications of ketenes have been carried out in our group.

Active collaborations are ongoing with scientists in Australia (UQ and CSIRO), China (Suzhou), France (Pau), Germany (Oldenburg), Japan (Hiroshima), Spain (Donostia - San Sebastian), and Portugal (Coimbra).

Craig M. Williams was born in Adelaide, Australia. He received his B.Sc. (Hons) degree in chemistry in 1994 from Flinders University. In 1997, he was awarded his Ph.D. in organic chemistry from the same institution under the supervision of Professor Rolf H. Prager. He undertook post-doctoral studies as an Alexander von Humboldt Fellow working with Professor Armin de Meijere at the Georg-August-Universität, Göttingen, Germany, from 1997 to 1999. In early 1999, he accepted a second post-doctoral fellowship at the Australian National University with Professor Lewis N. Mander.

Professor Williams has held an academic position at the University of Queensland since 2000, and during this time has won a number of awards including a Thieme Chemistry Journals Award in 2007, an Australian Research Council Future Fellowship award in 2011, and the Award for Outstanding Contribution to Research (SCMB, UQ, 2019). The Williams research group explores numerous interests within the discipline of organic chemistry (e.g. medicinal chemistry, fundamental molecules, natural productisolation, microelectronics, drug and agrichemical development, impact sensitive molecules) enabled by organic synthesis refined through the construction of biologically active complex natural products (diterpenes, polyketides, alkaloids), and designs synthetic methodology to assist in this endeavour (synthetic transformations and reagents). Professor Williams especially enjoys teaching whole molecule retrosynthesis to undergraduate and post-graduate students.

​Dr James Wood's research focuses primarily on the design and synthesis of organic ligands to complex inorganic radioisotopes for radiopharmaceutical applications. His work spans across the design and synthesis of these ligands, through to radiolabelling of these compounds and assessing them within animal models. He is particularly interested in applications of these ligands that grant greater flexability or utility to diagnostic and therapeutic platforms.

James works within the ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals at the Centre for Advanced Imaging, working with industry partners to excelerate the production of novel radiopharmaceuticals.

Dr Zyta Ziora received PhD (Wroclaw University of Science & Technology, Poland) in chemistry and has wide range of experience in development of antimalarial therapeutics (the University of Montpellier, France), antibacterial agents, enzyme inhibitors and drug candidates against Alzheimer disease (Kyoto Pharmaceutical University, Japan). Her research time is currently dedicated mainly to projects devoted to the modification of existing antibiotics, and complexing them with additional antimicrobial agents, like metal ions, to produce more potent alternatives and by this to overcome the drug resistance of superbugs. She is also working on alternative to antibiotics nature-derived compounds with antimicrobial and anticancer potency, such poliphenolic derivatives to control tyrosinase function.